Annume Vitality Lab · Research Library

The Longevity Compendium

Metabolic research: key findings and limits

Selected starting points for reading the evidence. These summaries cover selected studies; other library entries have their own source dates and have not all been re-reviewed.

Read the study findings and primary sources

Semaglutide: cardiovascular outcomes in SELECT

SELECT enrolled 17,604 adults aged 45 or older with a body mass index of at least 27, established cardiovascular disease and no diabetes history. Participants received injectable semaglutide or placebo alongside standard care.

Over a mean 39.8 months of follow-up, the first cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 569/8,803 participants (6.5%) with semaglutide versus 701/8,801 (8.0%) with placebo. The absolute difference was about 1.5 percentage points; the hazard ratio was 0.80 (95% CI 0.72–0.90). Adverse events led to permanent treatment discontinuation in 16.6% versus 8.2%.

FDA added a cardiovascular-risk reduction indication for Wegovy injection in March 2024 for adults with established cardiovascular disease and overweight or obesity, alongside a reduced-calorie diet and increased physical activity. This combined trial outcome does not establish the same benefit for each component or longer life in healthy adults. It is not a complete safety guide.

Established evidence added to this library November 16, 2026; not a newly reported trial. SELECT was funded by Novo Nordisk.

Cerebrolysin: not FDA approved

Cerebrolysin is not FDA approved. Its manufacturer states that it is not approved for sale or distribution in the United States. A 2020 FDA warning letter also identifies Cerebrolysin among substances that were not components of FDA-approved human drugs. Authorization in another country is not FDA approval.

Regulatory label corrected November 16, 2026. This status note is not an assessment of efficacy or a treatment recommendation.

Retatrutide: weight loss is not an approval decision

In TRIUMPH-1, 2,339 adults with obesity, or overweight with a weight-related complication, without diabetes were randomized to retatrutide or placebo. At 80 weeks, the 12 mg study group had an average body-weight change of −25.0%, compared with −3.9% with placebo, using the treatment-regimen analysis, which includes treatment discontinuation. The 28.3% headline uses a different efficacy estimand and is not interchangeable. Gastrointestinal adverse events were common. Trial doses identify study groups; they are not instructions for use.

Retatrutide remains investigational. FDA states that it is not a component of an approved drug and cannot be used in compounding under federal law. These results do not establish longer life or benefit for healthy adults seeking longevity treatment.

The knee-osteoarthritis update covers the November 8 report’s pain, patient-reported function and safety findings, including its source limitations.

BELIEVE: body composition and muscle function differ

BELIEVE randomized 507 adults with obesity, or overweight with an obesity-related complication, excluding diabetes. Bimagrumab is an antibody that blocks activin type II receptors, affecting myostatin and activin signaling; it is broader than a direct myostatin inhibitor. At 48 weeks, the treatment-regimen analysis estimated lean-mass changes of −1.3 kg with bimagrumab 30 mg/kg plus semaglutide 2.4 mg versus −3.9 kg with semaglutide 2.4 mg alone. Fat-mass changes were −15.6 kg versus −9.6 kg.

These trial groups do not provide a treatment recommendation. DXA lean mass is not a direct measure of strength. The study does not establish consistent functional improvement, fracture prevention or longer life. Reported adverse events included muscle spasms, diarrhea and acne; semaglutide treatment was open label.

Related research: COURAGE and trevogrumab · Eloralintide and amylin research.

Educational summaries prepared with AI assistance; no article-specific physician review is claimed. Discuss treatment questions with a licensed clinician. How Annume handles evidence.

A reference spanning peptides, senolytics and longevity compounds. Evidence ranges from laboratory studies to clinical trials; source quality and approval status differ by entry.

Annume Blog: clear explanations and the latest research →

49Compounds
78Citations
13Categories